AstraZeneca Nabs Early FDA Approval for Blood Cancer Med

Oct 31, 2017

AstraZeneca has won approval from the U.S. Food and Drug and Administration (FDA) for Calquence (acalabrutinib), a new blood cancer drug. The approval comes several months earlier than expected.

AstraZeneca is required to pay $1.5 billion to shareholders of Acerta Pharma, the biotech company that discovered the treatment and that AstraZeneca bought a majority stake in 2015.

The FDA has approved Calquenceas a treatment for adults with a rare type of blood cancer called mantle cell lymphoma who have received at least one prior therapy.

According to AstraZeneca, it expected a U.S. approval decision by quarter one of 2018. Also, CEO Pascal Soriot characterized the approval as a landmark moment for AstraZeneca.

Read the Reuters report

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments